HS
GALT icon

HighVista Strategies’s Galectin Therapeutics GALT Stock Holding History

HighVista Strategies’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-25,300
Closed -$50K – 106
2020
Q1 		$50K Sell
25,300
-4,900
-16% -$11.9K 0.05% 44
2019
Q4 		$86K Buy
30,200
+12,000
+66% +$41.7K 0.07% 89
2019
Q3 		$67K Buy
+18,200
New +$65.8K 0.05% 99

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HighVista Strategies's GALT Position: Q2 2020 in Review

HighVista Strategies sold out of Galectin Therapeutics (GALT) in Q2 2020, closing a stake of 25,300 shares — an estimated $50K sold.

HighVista Strategies first reported a position in GALT in Q3 2019 and held it in 3 quarters. The position peaked at $86K in Q4 2019. 75 funds tracked by Wall St. Rank hold GALT as of Q2 2020.

  • HighVista Strategies reported no remaining Galectin Therapeutics position as of Q2 2020 after selling out during the quarter.
  • HighVista Strategies sold 25,300 Galectin Therapeutics shares in Q2 2020, an estimated $50K.
  • HighVista Strategies first reported a position in Galectin Therapeutics in Q3 2019 and held it in 3 quarters.
  • HighVista Strategies's Galectin Therapeutics position peaked at $86K in Q4 2019.
  • 75 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2020.

Based on HighVista Strategies's 13F filing for Q2 2020, filed 14 Aug 2020.